Log In
Print
BCIQ
Print
Print this Print this
 

Civacir

  Manage Alerts
Collapse Summary General Information
Company Biotest AG
DescriptionHCV neutralizing polyclonal antibody
Molecular Target Not available
Mechanism of ActionBinds viral antigens
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsPrevent HCV infection in liver transplant patients; Prevent recurrence of hepatitis C-related liver disease in HCV positive liver transplant recipients or in patients who received an HCV-positive liver; Treat and prevent HCV infection
Regulatory Designation

U.S. - Orphan Drug (Prevent HCV infection in liver transplant patients);
EU - Orphan Drug (Prevent HCV infection in liver transplant patients)

Partner

Kedrion Group


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today